Tri Chemical Laboratories (4369) Q4 2026 earnings summary

Executive summary

• Net sales rose 26.3% year-over-year to ¥23,883 million for the fiscal year ended January 31, 2026, with operating profit up 12.3% to ¥5,902 million and profit attributable to owners of parent up 11.1% to ¥5,515 million.

• Comprehensive income increased 14.2% year-over-year to ¥5,699 million.

• The business operates as a single segment focused on high-purity chemicals for semiconductor manufacturing, with significant growth in China and Taiwan.

Financial highlights

• Gross profit increased from ¥8,012 million to ¥9,019 million year-over-year.

• Ordinary profit rose 7.7% to ¥7,090 million, and basic earnings per share increased to ¥169.72 from ¥152.69.

• Total assets grew to ¥47,274 million from ¥36,944 million, and net assets rose to ¥36,149 million from ¥31,587 million.

• Equity-to-asset ratio decreased to 76.5% from 85.5%.

• Cash and cash equivalents at year-end declined to ¥7,279 million from ¥9,439 million.

Outlook and guidance

• Forecast for fiscal year ending January 31, 2027: net sales of ¥27,000 million (up 13.1%), operating profit of ¥6,000 million (up 1.7%), and profit attributable to owners of parent of ¥4,600 million (down 16.6%).

• Basic earnings per share forecasted at ¥141.55 for the next fiscal year.